Today's Daily Dose brings you news about Aurinia initiating a trial of its lead candidate Voclosporin in kidney transplant recipients with COVID-19, Exact Sciences' Q3 financial results, FDA approval of Kala Pharma's EYSUVIS 0.25% for dry eye disease, update on Novavax's COVID-19 vaccine trials, and Scholar Rock's spinal muscular atrophy trial results.
from RTT - Biotech https://ift.tt/3kN70hK
via IFTTT
No comments:
Post a Comment